Novo Nordisk's CagriSema Reduces HbA1c and Weight in Type 2 Diabetes Trials

Phase 3 results for Novo Nordisk's investigational treatment, CagriSema, show significant reductions in HbA1c and body weight for adults with type 2 diabetes. The once-weekly combination therapy, an amylin analog with a GLP-1 receptor agonist, demonstrated positive outcomes across multiple trials. These findings, presented at a major scientific session and published in medical journals, highlight its potential as a new therapeutic option.